Caroline M. Moore

Dr. Caroline M. Moore


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in European Urology
Verified
Journal Article
Closed access
ISIvo G. Schoots
Ivo G. Schoots
NPNeophytos Petrides
Neophytos Petrides
FGFrancesco Giganti
Francesco Giganti
LBLeonard P. Bokhorst
Leonard P. Bokhorst
ARAntti Rannikko
Antti Rannikko
CMCaroline M. Moore
Caroline M. Moore

1 April 2017 in European Urology
Verified
Journal Article
Closed access
CMCaroline M. Moore
Caroline M. Moore
FGFrancesco Giganti
Francesco Giganti
PAPeter Albertsen
Peter Albertsen
CAClare Allen
Clare Allen
CBChris Bangma
Chris Bangma
ISIvo Schoots
Ivo Schoots

12 February 2019 in BJU International
Verified
Journal Article
Open access
PDF file
ASArmando Stabile
Armando Stabile
COClement Orczyk
Clement Orczyk
FHFeargus Hosking‐Jervis
Feargus Hosking‐Jervis
FGFrancesco Giganti
Francesco Giganti
MAManit Arya
Manit Arya
CMCaroline M. Moore
Caroline M. Moore
Objective: To report medium‐term oncological outcomes in men receiving primary focal treatment with high‐intensity focused ultrasonography ( HIFU ) for prostate cancer ( PC a). Patients and Methods: Consecutive patients with PC a treated with primary focal HIFU at two centres by six treating clinicians were assessed. Patients were submitted to either focal ablation or hemi‐ablation using HIFU (Sonablate 500). The primary objective of the study was to assess medium‐term oncological outcomes, defined as overall survival, freedom from biopsy failure, freedom from any further treatment and freedom from radical treatment after focal HIFU . The secondary objective was to evaluate the changes in pathological features among patients treated with focal HIFU over time. We also assessed the relationship between year of surgery and 5‐year retreatment probability. Results: A total of 1032 men treated between November 2005 and October 2017 were assessed . The median age was 65 years and median prostate‐specific antigen level was 7 ng/mL. The majority of patients had a Gleason score of 3 + 4 or above (80.3%). The median (interquartile range) follow‐up was 36 (14–64) months. The overall survival rates at 24, 60 and 96 months were 99%, 97% and 97%, respectively. Freedom from biopsy failure, defined as absence of Gleason 3 + 4 disease, was 84%, 64% and 54% at 24, 60 and 96 months. Freedom from any further treatment was 85%, 59% and 46% at 24, 60 and 96 months, respectively. Approximately 70% of patients who were retreated received a second focal treatment. Freedom from radical treatment was 98%, 91% and 81% at 24, 60 and 96 months. During the study period, we observed an increase in the proportion of patients undergoing focal HIFU with Gleason 3 + 4 disease and with T2 stage disease as defined by multiparametric magnetic resonance imaging. Finally, there was a reduction over time in the proportion of patients undergoing re‐treatment within 5 years of first treatment. Conclusions: Focal HIFU for PC a is a feasible therapeutic strategy, with acceptable survival and oncological results and a reduction in the 5‐year retreatment rates over the last decade. Re‐do focal treatment is a feasible technique whose functional and oncological outcomes have still to be evaluated.

19 May 2014 in BJU International
Verified
Journal Article
Open access
PDF file
CMCaroline M. Moore
Caroline M. Moore
AAAbel‐Rahmene Azzouzi
Abel‐Rahmene Azzouzi
EBEric Barret
Eric Barret
AVArnauld Villers
Arnauld Villers
GMGordon H. Muir
Gordon H. Muir
MEMark Emberton
Mark Emberton
Objective: To determine the optimal drug and light dose for prostate ablation using WST11 ( TOOKAD ® Soluble) for vascular‐targeted photodynamic ( VTP ) therapy in men with low‐risk prostate cancer. Patients and Methods: In all, 42 men with low‐risk prostate cancer were enrolled in the study but two who underwent anaesthesia for the procedure did not receive the drug or light dose. Thus, 40 men received a single dose of 2, 4 or 6 mg/kg WST11 activated by 200 J/cm light at 753 nm. WST11 was given as a 10‐min intravenous infusion. The light dose was delivered using cylindrical diffusing fibres within hollow plastic needles positioned in the prostate using transrectal ultrasonography ( TRUS ) guidance and a brachytherapy template. Magnetic resonance imaging ( MRI ) was used to assess treatment effect at 7 days, with assessment of urinary function (International Prostate Symptom Score [ IPSS ]), sexual function (International Index of Erectile Function [ IIEF ]) and adverse events at 7 days, 1, 3 and 6 months after VTP . TRUS ‐guided biopsies were taken at 6 months. Results: In all, 39 of the 40 treated men completed the follow‐up. The Day‐7 MRI showed maximal treatment effect (95% of the planned treatment volume) in men who had a WST11 dose of 4 mg/kg, light dose of 200 J/cm and light density index ( LDI ) of >1. In the 12 men treated with these parameters, the negative biopsy rate was 10/12 (83%) at 6 months, compared with 10/26 (45%) for the men who had either a different drug dose (10 men) or an LDI of <1 (16). Transient urinary symptoms were seen in most of the men, with no significant difference in IPSS score between baseline and 6 months after VTP . IIEF scores were not significantly different between baseline and 6 months after VTP . Conclusion: Treatment with 4 mg/kg TOOKAD Soluble activated by 753 nm light at a dose of 200 J/cm and an LDI of >1 resulted in treatment effect in 95% of the planned treatment volume and a negative biopsy rate at 6 months of 10/12 men (83%).

5 April 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
AAAqua Asif
Aqua Asif
ANArjun Nathan
Arjun Nathan
ANAlexander Ng
Alexander Ng
PKPramit Khetrapal
Pramit Khetrapal
VCVinson Wai-Shun Chan
Vinson Wai-Shun Chan
VKVeeru Kasivisvanathan
Veeru Kasivisvanathan
Introduction Prostate MRI is a well-established tool for the diagnostic work-up for men with suspected prostate cancer (PCa). Current recommendations advocate the use of multiparametric MRI (mpMRI), which is composed of three sequences: T2-weighted sequence (T2W), diffusion-weighted sequence (DWI) and dynamic contrast-enhanced sequence (DCE). Prior studies suggest that a biparametric MRI (bpMRI) approach, omitting the DCE sequences, may not compromise clinically significant cancer detection, though there are limitations to these studies, and it is not known how this may affect treatment eligibility. A bpMRI approach will reduce scanning time, may be more cost-effective and, at a population level, will allow more men to gain access to an MRI than an mpMRI approach. Methods Prostate Imaging Using MRI±Contrast Enhancement (PRIME) is a prospective, international, multicentre, within-patient diagnostic yield trial assessing whether bpMRI is non-inferior to mpMRI in the diagnosis of clinically significant PCa. Patients will undergo the full mpMRI scan. Radiologists will be blinded to the DCE and will initially report the MRI using only the bpMRI (T2W and DWI) sequences. They will then be unblinded to the DCE sequence and will then re-report the MRI using the mpMRI sequences (T2W, DWI and DCE). Men with suspicious lesions on either bpMRI or mpMRI will undergo prostate biopsy. The main inclusion criteria are men with suspected PCa, with a serum PSA of ≤20 ng/mL and without prior prostate biopsy. The primary outcome is the proportion of men with clinically significant PCa detected (Gleason score ≥3+4 or Gleason grade group ≥2). A sample size of at least 500 patients is required. Key secondary outcomes include the proportion of clinically insignificant PCa detected and treatment decision. Ethics and dissemination Ethical approval was obtained from the National Research Ethics Committee West Midlands, Nottingham (21/WM/0091). Results of this trial will be disseminated through peer-reviewed publications. Participants and relevant patient support groups will be informed about the results of the trial. Trial registration number NCT04571840.

1 October 2023 in Radiology
Verified
Journal Article
Closed access
FGFrancesco Giganti
Francesco Giganti
ANAlexander Ng
Alexander Ng
AAAqua Asif
Aqua Asif
VCVinson Wai-Shun Chan
Vinson Wai-Shun Chan
MRMarimo Rossiter
Marimo Rossiter
YLYann Lebras
Yann Lebras
Background High variability in prostate MRI quality might reduce accuracy in prostate cancer detection. Purpose To prospectively evaluate the quality of MRI scanners taking part in the quality control phase of the global PRIME (Prostate Imaging Using MRI ± Contrast Enhancement) trial using the Prostate Imaging Quality (PI-QUAL) standardized scoring system, give recommendations on how to improve the MRI protocols, and establish whether MRI quality could be improved by these recommendations. Materials and Methods In the prospective clinical trial (PRIME), for each scanner, centers performing prostate MRI submitted five consecutive studies and the MRI protocols (phase I). Submitted data were evaluated in consensus by two expert genitourinary radiologists using the PI-QUAL scoring system that evaluates MRI diagnostic quality using five points (1 and 2 = nondiagnostic; 3 = sufficient; 4 = adequate, 5 = optimal) between September 2021 and August 2022. Feedback was provided for scanners not achieving a PI-QUAL 5 score, and centers were invited to resubmit new imaging data using the modified protocol (phase II). Descriptive comparison of outcomes was made between the MRI scanners, feedback provided, and overall PI-QUAL scores. Results In phase I, 41 centers from 18 countries submitted a total of 355 multiparametric MRI studies from 71 scanners, with nine (13%) scanners achieving a PI-QUAL score of 3, 39 (55%) achieving a score of 4, and 23 (32%) achieving a score of 5. Of the 48 (n = 71 [68%]) scanners that received feedback to improve, the dynamic contrast-enhanced sequences were those that least adhered to the Prostate Imaging Reporting and Data System, version 2.1, criteria (44 of 48 [92%]), followed by diffusion-weighted imaging (20 of 48 [42%]) and T2-weighted imaging (19 of 48 [40%]). In phase II, 36 centers from 17 countries resubmitted revised studies, resulting in a total of 62 (n = 64 [97%]) scanners with a final PI-QUAL score of 5. Conclusion Substantial variation in global prostate MRI acquisition parameters as a measure of quality was observed, particularly with DCE sequences. Basic evaluation and modifications to MRI protocols using PI-QUAL can lead to substantial improvements in quality. Clinical trial registration no. NCT04571840 Published under a CC BY 4.0 license. Supplemental material is available for this article. See also the editorial by Almansour and Chernyak in this issue.